ZA201009284B - Antiviral salts - Google Patents

Antiviral salts

Info

Publication number
ZA201009284B
ZA201009284B ZA2010/09284A ZA201009284A ZA201009284B ZA 201009284 B ZA201009284 B ZA 201009284B ZA 2010/09284 A ZA2010/09284 A ZA 2010/09284A ZA 201009284 A ZA201009284 A ZA 201009284A ZA 201009284 B ZA201009284 B ZA 201009284B
Authority
ZA
South Africa
Prior art keywords
antiviral
salts
antiviral salts
Prior art date
Application number
ZA2010/09284A
Other languages
English (en)
Inventor
Jane Ryan
Margaret Anne Butt
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of ZA201009284B publication Critical patent/ZA201009284B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2010/09284A 2008-05-27 2010-12-23 Antiviral salts ZA201009284B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5634108P 2008-05-27 2008-05-27
PCT/AU2009/000663 WO2009143571A1 (en) 2008-05-27 2009-05-27 Antiviral salts

Publications (1)

Publication Number Publication Date
ZA201009284B true ZA201009284B (en) 2012-06-27

Family

ID=41376478

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/09284A ZA201009284B (en) 2008-05-27 2010-12-23 Antiviral salts

Country Status (14)

Country Link
US (2) US8580791B2 (enExample)
EP (1) EP2297141B1 (enExample)
JP (1) JP5469662B2 (enExample)
KR (1) KR20110019759A (enExample)
CN (1) CN102046621B (enExample)
AU (1) AU2009253738B2 (enExample)
BR (1) BRPI0912038A2 (enExample)
CA (1) CA2725618C (enExample)
CO (1) CO6280534A2 (enExample)
EA (1) EA020455B1 (enExample)
MX (1) MX2010013019A (enExample)
NZ (1) NZ590286A (enExample)
WO (1) WO2009143571A1 (enExample)
ZA (1) ZA201009284B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011938A (es) * 2010-04-15 2013-01-28 Biota Scient Management Compuesto para tratamiento de condicion o enfermedad respiratoria.
EP2585067B1 (en) 2010-06-25 2017-08-09 Biota Scientific Management Pty Ltd Compound for the treatment of enteroviruses
CN102617462B (zh) * 2012-02-28 2014-02-12 南京大学 特异性抑制肌肉微小核糖核酸的化合物及其合成方法和应用
KR20180038571A (ko) 2014-06-20 2018-04-16 아비라겐 테라퓨틱스, 인코포레이티드 [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태
US20250281519A1 (en) * 2021-05-05 2025-09-11 Emory University Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto
US20240350487A1 (en) * 2023-03-13 2024-10-24 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170387B (it) 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB2162522B (en) 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5545653A (en) * 1995-06-07 1996-08-13 Eli Lilly And Company Anti-viral compounds
US5693661A (en) * 1995-06-07 1997-12-02 Eli Lilly And Company Anti-viral compounds
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
AU6031898A (en) * 1997-01-22 1998-08-07 Eli Lilly And Company Anti-viral compounds
AU7715198A (en) * 1997-06-04 1998-12-21 Eli Lilly And Company Anti-viral compounds
US6358971B1 (en) * 1998-05-20 2002-03-19 Eli Lilly And Company Anti-viral compounds
SK17482000A3 (sk) * 1998-05-20 2005-03-04 Eli Lilly And Company Antivírusové zlúčeniny, spôsob inhibície vírusov a farmaceutický prípravok
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents

Also Published As

Publication number Publication date
KR20110019759A (ko) 2011-02-28
EP2297141B1 (en) 2015-10-21
AU2009253738A1 (en) 2009-12-03
WO2009143571A1 (en) 2009-12-03
JP2011520991A (ja) 2011-07-21
US8580791B2 (en) 2013-11-12
US9206171B2 (en) 2015-12-08
EA020455B1 (ru) 2014-11-28
CA2725618A1 (en) 2009-12-03
JP5469662B2 (ja) 2014-04-16
AU2009253738B2 (en) 2012-12-13
MX2010013019A (es) 2011-03-21
CO6280534A2 (es) 2011-05-20
CN102046621B (zh) 2014-11-12
EA201001835A1 (ru) 2011-06-30
US20110144118A1 (en) 2011-06-16
EP2297141A1 (en) 2011-03-23
CA2725618C (en) 2016-04-12
CN102046621A (zh) 2011-05-04
US20140179710A1 (en) 2014-06-26
BRPI0912038A2 (pt) 2017-06-20
NZ590286A (en) 2011-08-26
EP2297141A4 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
HRP20171759T8 (hr) Antiviralni spojevi
GB0815968D0 (en) Antiviral agents
GB0900914D0 (en) Antiviral agents
ZA201103943B (en) Purine compounds
IL216026A0 (en) Heterocyckic antiviral compounds
ZA201009284B (en) Antiviral salts
GB0803707D0 (en) Antiviral agent
GB0723609D0 (en) Antiviral
HK1155437A (zh) 抗病毒盐
GB0813850D0 (en) Salts
IL192335A0 (en) Antiviral compounds
GB0819528D0 (en) Antiviral compounds
GB0816600D0 (en) Antiviral compounds
GB0814762D0 (en) Antiviral agents
GB0714728D0 (en) Salts
GB0906209D0 (en) Antiviral compounds
GB0914473D0 (en) Antiviral compounds
GB0908677D0 (en) Antiviral compounds